Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

被引：109

作者：

Rassy, Elie ^{[2
,3
]}

Flippot, Ronan ^{[2
]}

Albiges, Laurence ^{[1
]}

机构：

[1] Univ Paris Saclay, Dept Canc Med, Gustave Roussy Inst, 114 Rue Edouard Vaillant, F-94805 Villejuif, France

[2] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France

[3] St Joseph Univ, Dept Med Oncol, Beirut, Lebanon

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2020年 / 12卷

关键词：

angiogenesis; combination; immune checkpoint inhibitors; immunotherapy; renal cell carcinoma; tyrosine kinase inhibitors; CLINICAL-PRACTICE GUIDELINES; ENDOTHELIAL GROWTH-FACTOR; T-CELLS; INTERFERON-ALPHA; PHASE-III; CANCER; SUNITINIB; VEGF; BEVACIZUMAB; EXPRESSION;

D O I：

10.1177/1758835920907504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint inhibitors (ICIs). Both treatment options have improved outcomes of patients and modified the natural history of mRCC. Clinical investigations have focused on evaluating combination regimens containing ICIs and VEGFR-directed TKIs. Namely, the combinations of axitinib plus pembrolizumab (KEYNOTE-426) and axitinib plus avelumab (JAVELIN RENAL 101) have shown improved outcomes compared with sunitinib in treatment-naive patients with mRCC. In this review, we discuss the clinical data of single-agent TKIs and ICIs in mRCC and the rationale for the combination ICIs and TKIs based on preclinical and clinical evidence. We also explore the current challenges for regimen selection and development of predictive biomarkers.

引用

页数：13

共 75 条

[71] Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis [J].

Turajlic, Samra ;

Litchfield, Kevin ;

Xu, Hang ;

Rosenthal, Rachel ;

McGranahan, Nicholas ;

Reading, James L. ;

Wong, Yien Ning S. ;

Rowan, Andrew ;

Kanu, Nnennaya ;

Al Bakir, Maise ;

Chambers, Tim ;

Salgado, Roberto ;

Savas, Peter ;

Loi, Sherene ;

Birkbak, Nicolai J. ;

Sansregret, Laurent ;

Gore, Martin ;

Larkin, James ;

Quezada, Sergio A. ;

Swanton, Charles .

LANCET ONCOLOGY, 2017, 18 (08) :1009-1021

[72] VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors [J].

Voron, Thibault ;

Colussi, Orianne ;

Marcheteau, Elie ;

Pernot, Simon ;

Nizard, Mevyn ;

Pointet, Anne-Laure ;

Latreche, Sabrina ;

Bergaya, Sonia ;

Benhamouda, Nadine ;

Tanchot, Corinne ;

Stockmann, Christian ;

Combe, Pierre ;

Berger, Anne ;

Zinzindohoue, Franck ;

Yagita, Hideo ;

Tartour, Eric ;

Taieb, Julien ;

Terme, Magali .

JOURNAL OF EXPERIMENTAL MEDICINE, 2015, 212 (02) :139-148

[73] Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo [J].

Yasuda, S. ;

Sho, M. ;

Yamato, I. ;

Yoshiji, H. ;

Wakatsuki, K. ;

Nishiwada, S. ;

Yagita, H. ;

Nakajima, Y. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 172 (03) :500-506

[74] Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors [J].

Young, Matthew D. ;

Mitchell, Thomas J. ;

Braga, Felipe A. Vieira ;

Tran, Maxine G. B. ;

Stewart, Benjamin J. ;

Ferdinand, John R. ;

Collord, Grace ;

Botting, Rachel A. ;

Popescu, Dorin-Mirel ;

Loudon, Kevin W. ;

Vento-Tormo, Roser ;

Stephenson, Emily ;

Cagan, Alex ;

Farndon, Sarah J. ;

Velasco-Herrera, Martin Del Castillo ;

Guzzo, Charlotte ;

Richoz, Nathan ;

Mamanova, Lira ;

Aho, Tevita ;

Armitage, James N. ;

Riddick, Antony C. P. ;

Mushtaq, Imran ;

Farrell, Stephen ;

Rampling, Dyanne ;

Nicholson, James ;

Filby, Andrew ;

Burge, Johanna ;

Lisgo, Steven ;

Maxwell, Patrick H. ;

Lindsay, Susan ;

Warren, Anne Y. ;

Stewart, Grant D. ;

Sebire, Neil ;

Coleman, Nicholas ;

Haniffa, Muzlifah ;

Teichmann, Sarah A. ;

Clatworthy, Menna ;

Behjati, Sam .

SCIENCE, 2018, 361 (6402) :594-+

[75] Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond [J].

Zhu, Jason ;

Armstrong, Andrew J. ;

Friedlander, Terence W. ;

Kim, Won ;

Pal, Sumanta K. ;

George, Daniel J. ;

Zhang, Tian .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

← 1 2 3 4 5 6 7 8 →